- Home
- TLSA vs GNTA Comparison
TLSA vs GNTA Comparison
Compare TLSA & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | GNTA |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United Kingdom | Italy |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.3M | 19.9M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLSA | GNTA |
|---|---|---|
| Price | $1.18 | $1.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 206.0K | ★ 1.5M |
| Earning Date | 05-04-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $0.55 |
| 52 Week High | $2.60 | $10.00 |
Technical Indicators
Market Signals| Indicator | TLSA | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 58.36 |
| Support Level | $1.11 | $1.31 |
| Resistance Level | $1.44 | $2.20 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 60.42 | 65.22 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.